These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 26330357)

  • 21. Novel Use for DOG1 in Discriminating Breast Invasive Carcinoma from Noninvasive Breast Lesions.
    Cheng H; Yang S; Qu Z; Zhou S; Ruan Q
    Dis Markers; 2016; 2016():5628176. PubMed ID: 27041791
    [TBL] [Abstract][Full Text] [Related]  

  • 22. p63 and CD10: reliable markers in discriminating benign sclerosing lesions from tubular carcinoma of the breast?
    de Moraes Schenka NG; Schenka AA; de Souza Queiroz L; de Almeida Matsura M; Alvarenga M; Vassallo J
    Appl Immunohistochem Mol Morphol; 2006 Mar; 14(1):71-7. PubMed ID: 16540734
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phenotypic alterations in ductal carcinoma in situ-associated myoepithelial cells: biologic and diagnostic implications.
    Hilson JB; Schnitt SJ; Collins LC
    Am J Surg Pathol; 2009 Feb; 33(2):227-32. PubMed ID: 18936688
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The phosphorylated form of connexin43 is up-regulated in breast hyperplasias and carcinomas and in their neoformed capillaries.
    Gould VE; Mosquera JM; Leykauf K; Gattuso P; Dürst M; Alonso A
    Hum Pathol; 2005 May; 36(5):536-45. PubMed ID: 15948121
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A subset of malignant phyllodes tumors express p63 and p40: a diagnostic pitfall in breast core needle biopsies.
    Cimino-Mathews A; Sharma R; Illei PB; Vang R; Argani P
    Am J Surg Pathol; 2014 Dec; 38(12):1689-96. PubMed ID: 25046342
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adenomyoepithelial tumours and myoepithelial carcinomas of the breast--a spectrum of monophasic and biphasic tumours dominated by immature myoepithelial cells.
    Hungermann D; Buerger H; Oehlschlegel C; Herbst H; Boecker W
    BMC Cancer; 2005 Jul; 5():92. PubMed ID: 16050957
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phenotypic and Functional Characterization of Ductal Carcinoma In Situ-Associated Myoepithelial Cells.
    Rohilla M; Bal A; Singh G; Joshi K
    Clin Breast Cancer; 2015 Oct; 15(5):335-42. PubMed ID: 25700939
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phenotypic alterations in myoepithelial cells associated with benign sclerosing lesions of the breast.
    Hilson JB; Schnitt SJ; Collins LC
    Am J Surg Pathol; 2010 Jun; 34(6):896-900. PubMed ID: 20463570
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thymidylate Synthase, a New Myoepithelial Biomarker for Breast Lesions.
    Guo R; Tian Y; Jin X; Huang X; Yang J
    Int J Surg Pathol; 2019 Dec; 27(8):852-858. PubMed ID: 31234664
    [No Abstract]   [Full Text] [Related]  

  • 30. Antibodies targeting p63 react specifically in the cytoplasm of breast epithelial cells exhibiting secretory differentiation.
    Bratthauer GL; Saenger JS; Strauss BL
    Histopathology; 2005 Dec; 47(6):611-6. PubMed ID: 16324199
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined evaluation of CK5/6, ER, p63, and MUC3 for distinguishing breast intraductal papilloma from ductal carcinoma in situ.
    Furuya C; Kawano H; Yamanouchi T; Oga A; Ueda J; Takahashi M
    Pathol Int; 2012 Jun; 62(6):381-90. PubMed ID: 22612506
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumour 63 protein (p63) in breast pathology: biology, immunohistochemistry, diagnostic applications, and pitfalls.
    Alkhayyat R; Abbas A; Quinn CM; Rakha EA
    Histopathology; 2024 Apr; 84(5):723-741. PubMed ID: 38012539
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of immunohistochemistry in the differential diagnosis of breast lesions.
    Moriya T; Kozuka Y; Kanomata N; Tse GM; Tan PH
    Pathology; 2009 Jan; 41(1):68-76. PubMed ID: 19089742
    [TBL] [Abstract][Full Text] [Related]  

  • 34. D2-40 expression by breast myoepithelium: potential pitfalls in distinguishing intralymphatic carcinoma from in situ carcinoma.
    Rabban JT; Chen YY
    Hum Pathol; 2008 Feb; 39(2):175-83. PubMed ID: 18206495
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of LGR5 in mammary myoepithelial cells and in triple-negative breast cancers.
    Lee HJ; Myung JK; Kim HS; Lee DH; Go HS; Choi JH; Koh HM; Lee SJ; Jang B
    Sci Rep; 2021 Sep; 11(1):17750. PubMed ID: 34493772
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of p63 and p40 (ΔNp63) as Basal, Squamoid, and Myoepithelial Markers in Salivary Gland Tumors.
    Owosho AA; Aguilar CE; Seethala RR
    Appl Immunohistochem Mol Morphol; 2016 Aug; 24(7):501-8. PubMed ID: 26230372
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The clinical use of a P63/cytokeratin7/18/cytokeratin5/14 antibody cocktail in diagnostic breast pathology.
    Reisenbichler ES; Ross JR; Hameed O
    Ann Diagn Pathol; 2014 Dec; 18(6):313-8. PubMed ID: 25224390
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Myoepithelial cells in the differential diagnosis of complex benign and malignant breast lesions: an immunohistochemical study.
    Gottlieb C; Raju U; Greenwald KA
    Mod Pathol; 1990 Mar; 3(2):135-40. PubMed ID: 1691493
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Uroplakin II (UPII), GATA3, and p40 are Highly Sensitive Markers for the Differential Diagnosis of Invasive Urothelial Carcinoma.
    Hoang LL; Tacha D; Bremer RE; Haas TS; Cheng L
    Appl Immunohistochem Mol Morphol; 2015; 23(10):711-6. PubMed ID: 25611245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.